By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Calcium channel blocker > Lercanidipine

Lercanidipine

GMJ
Last updated: 02/06/2026 14:31
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|645 words

What is Lercanidipine?

Lercanidipine is a calcium channel blocker medication primarily used to treat high blood pressure (hypertension). It belongs to the dihydropyridine class of calcium channel blockers, which are known for their selective action on blood vessels. This medication helps reduce cardiovascular risk by lowering blood pressure through its effects on arterial smooth muscle.

Uses

  • Hypertension: The primary indication for lercanidipine is treating mild to moderate high blood pressure, either as monotherapy or in combination with other antihypertensive medications.
  • Cardiovascular protection: By controlling blood pressure, lercanidipine helps reduce the risk of heart attack, stroke, and other cardiovascular complications.
  • Isolated systolic hypertension: Particularly effective in elderly patients who have elevated systolic blood pressure with normal diastolic readings.
  • Combination therapy: Often used alongside ACE inhibitors, diuretics, or beta-blockers when single-drug therapy is insufficient to control blood pressure.

How it works

Lercanidipine blocks calcium channels in the smooth muscle cells of blood vessel walls, preventing calcium from entering these cells. Without adequate calcium, the blood vessels cannot contract as forcefully, leading to vasodilation (widening of blood vessels). This reduction in vascular resistance allows blood to flow more easily, thereby lowering blood pressure and reducing the workload on the heart.

Side effects

Common side effects include:

  • Swelling of ankles, feet, or legs (peripheral edema)
  • Headache
  • Dizziness or lightheadedness
  • Flushing or feeling of warmth
  • Fatigue or weakness
  • Nausea
  • Heart palpitations
  • Abdominal pain

Serious side effects to watch for:

Submit Your Paper
GMJ_Submit_Banner
  • Severe hypotension (dangerously low blood pressure)
  • Chest pain or worsening angina
  • Irregular heartbeat or arrhythmias
  • Severe allergic reactions with difficulty breathing or swallowing
  • Severe swelling that may indicate heart failure

Warnings and precautions

  • Liver impairment: Patients with severe liver disease should avoid lercanidipine, as the medication is extensively metabolized by the liver. Dose adjustments may be necessary for those with mild to moderate liver dysfunction.
  • Pregnancy and breastfeeding: Lercanidipine is not recommended during pregnancy or breastfeeding due to insufficient safety data. Alternative antihypertensive medications are preferred for pregnant women.
  • Heart conditions: Caution is advised in patients with severe aortic stenosis, unstable angina, or recent heart attack, as the medication may worsen these conditions.
  • Elderly patients: Older adults may be more sensitive to blood pressure-lowering effects and should start with lower doses to prevent excessive hypotension.
  • Kidney disease: While dose adjustment is typically not required for kidney impairment, patients should be monitored closely for excessive blood pressure reduction.

Interactions

  • CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin): These medications can significantly increase lercanidipine levels, potentially causing dangerous drops in blood pressure.
  • Grapefruit juice: Can increase drug absorption and enhance blood pressure-lowering effects, potentially leading to hypotension.
  • Other antihypertensive medications: Combining with ACE inhibitors, diuretics, or beta-blockers may cause additive blood pressure reduction requiring dose adjustments.
  • Rifampin: This antibiotic can reduce lercanidipine effectiveness by increasing its metabolism.
  • Digoxin: Lercanidipine may increase digoxin levels, requiring monitoring for signs of digoxin toxicity.
  • Cyclosporine: This immunosuppressant can increase lercanidipine concentrations and may have its own levels affected.
  • Alpha-blockers: Combination use may result in severe hypotension, particularly when starting treatment.
  • Carbamazepine: This anticonvulsant may reduce lercanidipine effectiveness by enhancing its metabolism.

Check interactions with the GMJ Interaction Checker

Dosage

The typical starting dose for adults is 10 mg once daily, taken in the morning before breakfast on an empty stomach. The dose may be increased to 20 mg once daily after 2-4 weeks if blood pressure control is inadequate. The maximum recommended dose is 20 mg daily. Elderly patients or those with liver impairment may require lower starting doses. Lercanidipine should be taken at least 15 minutes before meals, as food can significantly affect absorption. Always follow your healthcare provider’s specific dosing instructions, as individual requirements may vary based on blood pressure response and other medical conditions.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Lercanidipine." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/lercanidipine/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Traditional Chinese herb shows promise for androgenetic alopecia treatment

Traditional Chinese herb Polygonum multiflorum shows promise for treating androgenetic alopecia through…

Dual Doctor Couples Face Amplified Childcare Crisis in Medical Training

Dual doctor couples face amplified childcare challenges during medical training, with foundation…

Child Mortality Progress Stalls: 60 Countries Risk Missing 2030 UN Targets

New BMJ analysis reveals 60 countries unlikely to meet UN child survival…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Nifedipine

By
Prof. Giorgi Pkhakadze
02/06/2026

Amlodipine

By
Prof. Giorgi Pkhakadze
02/06/2026

Verapamil

By
Prof. Giorgi Pkhakadze
02/06/2026

Diltiazem

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up